Close

Orphazyme (ORPH) has received CRL from the FDA following its review of the new drug application for arimoclomol

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. V
6. BA
7. KMB
8. FI
9. MSCI
10. SPY


Go back to Orphazyme (ORPH) has received CRL from the FDA following its review of the new drug application for arimoclomol
(NASDAQ: ORPH) Delayed: 0.87 --0 (-0%)
Previous Close $0.87    52 Week High $ 
Open $0.87    52 Week Low $ 
Day High $0.87    P/E N/A 
Day Low $0.87    EPS $ 
Volume 100,917